Table 6

All cause discontinuations

Number (%) with outcome

Dosing (mg)

Number of trials

Sildenafil

Placebo

Relative risk (95% CI)

NNH (95% CI)

25

3

32/312 (10)

63/426 (15)

0.75 (0.50 to 1.11)

50

5

36/508 (7)

86/607 (14)

0.52 (0.36 to 0.76)

-14 (-9 to -28)

100

5

47/506 (9)

86/607 (14)

0.67 (0.47 to 0.95)

-20 (-12 to -89)

200

2

18/191 (9)

23/181 (13)

0.76 (0.43 to 1.35)

Dose optimised

5

52/517 (10)

104/524 (20)

0.50 (0.37 to 0.67)

-10 (-7 to -18)

Moore et al. BMC Urology 2002 2:6   doi:10.1186/1471-2490-2-6